BSE · 524640
Archit Organosys Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹37 Cr with net profit ₹2 Cr — a 5.53% net margin, versus 6.33% the period before.
Shareholding
As of 2026-06-30
- Promoter65.88%
- Public34.12%
8,959 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.9× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Chemicals · ranked #108 of 159 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Pidilite Industries Ltd. | ₹1,65,890 Cr | 67.35 | 15.31 | 22.61% | 16.77% |
| Solar Industries India Ltd. | ₹1,63,362 Cr | 93.51 | 26.02 | 26.72% | 17.05% |
| SRF Ltd. | ₹77,213 Cr | 34.46 | 5.5 | 13.07% | 13.01% |
| Linde India Limited | ₹56,603 Cr | 103.24 | 13.27 | 12.87% | 21.69% |
| Gujarat Fluorochemicals Ltd. | ₹48,279 Cr | 443.04 | 6.19 | 7.3% | 11.49% |
| Godrej Industries Ltd. | ₹44,101 Cr | 99.27 | 3.95 | 11.1% | 5.58% |
| Himadri Speciality Chem Limited | ₹38,370 Cr | 191.08 | 8.15 | 15.96% | 16.12% |
| Navin Fluorine International Ltd. | ₹37,898 Cr | 58.47 | 9.53 | 16.69% | 20.02% |
| Deepak Nitrite Ltd. | ₹22,422 Cr | 102.04 | 3.84 | 9.43% | 6.98% |
| Atul Ltd. | ₹20,029 Cr | 95.31 | 3.22 | 9.31% | 8.93% |
| Archit Organosys Ltd.(this company) | ₹118 Cr | 301.58 | 1.83 | 1.16% | 2.89% |
AI analysis
AI-generated · google/gemini-2.5-flashArchit Organosys Ltd. is listed on the Indian markets with a market capitalization of Rs 113 Cr. The company reported revenue of Rs 115.64 Cr and a profit margin of 288.9%. Its earnings per share (EPS) stands at Rs 0.19.
Positives
- +The company's return on equity (ROE) is 116.5%.
- +Promoter shareholding is 65.8792%, indicating a significant stake.
- +The debt-to-equity ratio is 0.46.
Negatives
- −The price-to-earnings (PE) ratio is high at 289.32.
- −The return on capital employed (ROCE) is relatively low at 3.8967%.
- −Net profit in Q4 Mar 2024 was negative at -Rs 0.46 Cr.
- −The stock is currently under ESM Stage 1 surveillance measures.
Financial Performance
Archit Organosys Ltd. reported total revenue of Rs 115.64 Cr. The company's net profit margin was 288.9%. Over the last four quarters (March 2025 to March 2026), revenue has fluctuated, with the highest in Dec 2025 at Rs 38.4 Cr and the lowest in Sept 2025 at Rs 32.86 Cr. Net profit for the same period ranged from Rs 1.54 Cr in Sept 2025 to Rs 2.43 Cr in Dec 2025.
Profitability & Returns
The company's return on equity (ROE) is 116.5%, while the return on capital employed (ROCE) is 3.8967%. Earnings per share (EPS) is reported at Rs 0.19. The price-to-earnings (PE) ratio stands at 289.32.
Balance Sheet
Archit Organosys Ltd. has a book value of Rs 31.26. The debt-to-equity ratio is 0.46, indicating the extent of debt financing relative to equity. The company does not offer a dividend yield.
Ownership & Pledges
Public shareholding stands at 34.1208%. There are no shares pledged by the promoters. The company has a total of 9446 shareholders.
Regulatory & Surveillance
Archit Organosys Ltd. is currently under ESM (Enhanced Surveillance Measure) Stage 1. This measure is implemented to enhance market integrity and to protect the interests of investors.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.